GlassScriptPhysician profile
Steven M Bobula
NPI 1700097565
$33,825.24
in general payments reported to CMS, 2019-2025
26 companies · $984 in 2025
The $984 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,467 · 2020: $5,042 · 2021: $9,002 · 2022: $5,506 · 2023: $6,787 · 2024: $1,036 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,370 · Consulting Fee: $3,251 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,175 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.46 |
| Consulting Fee | $3,251.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,175.00 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15,948.18 | 2020-2025 | Avycaz, Dalvance, Teflaro |
| Merck Sharp & Dohme LLC | $4,739.27 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Allergan, INC. | $4,629.50 | 2019-2020 | |
| Insmed, INC. | $3,643.45 | 2019-2025 | Arikayce |
| Csl Behring | $1,375.18 | 2019-2025 | Hizentra |
| Organogenesis INC. | $1,264.30 | 2019-2025 | Puraply, Puraply Wound Matrix |
| Viiv Healthcare Company | $715.96 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Smith+Nephew, INC. | $385.14 | 2021-2025 | Grafix Pl, Stravix, Collagenase Santyl |
| Melinta Therapeutics, LLC | $203.73 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Solventum Corporation | $129.06 | 2025 | Activ.A.C., Promogran Prisma |
| Shionogi INC | $105.21 | 2021-2025 | Fetroja |
| Astellas Pharma US INC | $101.55 | 2019-2025 | Cresemba |
| Gilead Sciences, INC. | $89.78 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $82.77 | 2024-2025 | Vowst |
| Paratek Pharmaceuticals, INC. | $73.42 | 2020-2025 | Nuzyra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $62.28 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
| Tetraphase Pharmaceuticals, INC. | $52.73 | 2019-2020 | |
| Kci USA, INC. | $51.76 | 2020-2021 | |
| La Jolla Pharmaceutical Company | $38.78 | 2024 | Xacduro, Xerava |
| Cumberland Pharmaceuticals, INC. | $29.23 | 2025 | Vibativ |
| Theratechnologies INC. | $28.20 | 2020-2021 | |
| Normatec Industries, LP | $21.43 | 2019 | |
| Aroa Biosurgery Incorporated | $16.56 | 2020 | |
| Pfizer INC. | $13.87 | 2025 | |
| Dynavax Technologies Corporation | $12.84 | 2023 | Heplisav-B |
| Mayne Pharma Commercial LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Bobula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.